• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility.

作者信息

Voice J K, Klemke R L, Le A, Jackson J H

机构信息

Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA.

出版信息

J Biol Chem. 1999 Jun 11;274(24):17164-70. doi: 10.1074/jbc.274.24.17164.

DOI:10.1074/jbc.274.24.17164
PMID:10358073
Abstract

Human cells contain four homologous Ras proteins, but it is unknown whether each of these Ras proteins participates in distinct signal transduction cascades or has different biological functions. To directly address these issues, we assessed the relative ability of constitutively active (G12V) versions of each of the four Ras homologs to activate the effector protein Raf-1 in vivo. In addition, we compared their relative abilities to induce transformed foci, enable anchorage-independent growth, and stimulate cell migration. We found a distinct hierarchy between the four Ras homologs in each of the parameters studied. The hierarchies were as follows: for Raf-1 activation, Ki-Ras 4B > Ki-Ras 4A >>> N-Ras > Ha-Ras; for focus formation, Ha-Ras >/= Ki-Ras 4A >>> N-Ras = Ki-Ras 4B; for anchorage-independent growth, Ki-Ras 4A >/= N-Ras >>> Ki-Ras 4B = Ha-Ras = no growth; and for cell migration, Ki-Ras 4B >>> Ha-Ras > N-Ras = Ki-Ras 4A = no migration. Our results indicate that the four Ras homologs significantly differ in their abilities to activate Raf-1 and induce distinctly different biological responses. These studies, in conjunction with our previous report that demonstrated that the Ras homologs can be differentially activated by upstream guanine nucleotide exchange factors (Jones, M. K., and Jackson, J. H. (1998) J. Biol. Chem. 273, 1782-1787), indicate that each of the four Ras proteins may qualitatively or quantitatively participate in distinct signaling cascades and have significantly different biological roles in vivo. Importantly, these studies also suggest for the first time that the distinct and likely cooperative biological functions of the Ki-ras-encoded Ki-Ras 4A and Ki-Ras 4B proteins may help explain why constitutively activating mutations of Ki-ras, but not N-ras or Ha-ras, are frequently detected in human carcinomas.

摘要

相似文献

1
Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility.
J Biol Chem. 1999 Jun 11;274(24):17164-70. doi: 10.1074/jbc.274.24.17164.
2
Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase.Ras亚型在激活Raf-1和磷酸肌醇3激酶的能力上存在差异。
J Biol Chem. 1998 Sep 11;273(37):24052-6. doi: 10.1074/jbc.273.37.24052.
3
Raf-1 is involved in the regulation of the interaction between guanine nucleotide exchange factor and Ha-ras. Evidences for a function of Raf-1 and phosphatidylinositol 3-kinase upstream to Ras.Raf-1参与鸟嘌呤核苷酸交换因子与Ha-ras之间相互作用的调节。有证据表明Raf-1和磷脂酰肌醇3激酶在Ras上游发挥作用。
J Biol Chem. 1998 Dec 25;273(52):34737-44. doi: 10.1074/jbc.273.52.34737.
4
TC21 and Ras share indistinguishable transforming and differentiating activities.TC21与Ras具有难以区分的转化和分化活性。
Oncogene. 1999 Mar 25;18(12):2107-16. doi: 10.1038/sj.onc.1202517.
5
A novel potential effector of M-Ras and p21 Ras negatively regulates p21 Ras-mediated gene induction and cell growth.一种新型的M-Ras和p21 Ras潜在效应器负向调节p21 Ras介导的基因诱导和细胞生长。
Oncogene. 2001 Jan 11;20(2):188-97. doi: 10.1038/sj.onc.1204053.
6
Cysteine-rich region of Raf-1 interacts with activator domain of post-translationally modified Ha-Ras.Raf-1的富含半胱氨酸区域与翻译后修饰的Ha-Ras的激活结构域相互作用。
J Biol Chem. 1995 Dec 22;270(51):30274-7. doi: 10.1074/jbc.270.51.30274.
7
Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane.通过将Raf靶向质膜可克服Ras对Raf激活的需求。
Nature. 1994 Jun 2;369(6479):411-4. doi: 10.1038/369411a0.
8
The role of Hsp90N, a new member of the Hsp90 family, in signal transduction and neoplastic transformation.热休克蛋白90家族新成员Hsp90N在信号转导和肿瘤转化中的作用。
J Biol Chem. 2002 Mar 8;277(10):8312-20. doi: 10.1074/jbc.M109200200. Epub 2001 Dec 20.
9
Coassociation of Rap1A and Ha-Ras with Raf-1 N-terminal region interferes with ras-dependent activation of Raf-1.Rap1A和Ha-Ras与Raf-1 N端区域的共结合会干扰Raf-1的ras依赖性激活。
J Biol Chem. 1997 May 2;272(18):11702-5. doi: 10.1074/jbc.272.18.11702.
10
Ki-ras and the characteristics of mouse lung tumors.Ki-ras与小鼠肺部肿瘤的特征
Mol Carcinog. 2000 Jul;28(3):156-67. doi: 10.1002/1098-2744(200007)28:3<156::aid-mc4>3.0.co;2-m.

引用本文的文献

1
Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance.KRAS靶向治疗的新范式:揭示对抗耐药性的策略。
Chin Med J (Engl). 2025 Sep 20;138(18):2243-2267. doi: 10.1097/CM9.0000000000003776. Epub 2025 Aug 18.
2
Targeting KRAS in colorectal cancer (Review).靶向结直肠癌中的KRAS(综述)。
Mol Clin Oncol. 2025 Jul 3;23(3):78. doi: 10.3892/mco.2025.2873. eCollection 2025 Sep.
3
PUF60-Regulated Isoform Switching of MAZ Modulates Gastric Cancer Cell Migration.PUF60调控的MAZ异构体转换调节胃癌细胞迁移。
Cancer Med. 2025 Jun;14(11):e70977. doi: 10.1002/cam4.70977.
4
Stem Cells in Cancer: From Mechanisms to Therapeutic Strategies.癌症中的干细胞:从机制到治疗策略
Cells. 2025 Apr 3;14(7):538. doi: 10.3390/cells14070538.
5
U2AF1 mutations rescue deleterious exon skipping induced by KRAS mutations.U2AF1突变可挽救由KRAS突变诱导的有害外显子跳跃。
bioRxiv. 2025 Mar 25:2025.03.21.644128. doi: 10.1101/2025.03.21.644128.
6
The differential interactomes of the KRAS splice variants identify BIRC6 as a ubiquitin ligase for KRAS4A.KRAS剪接变体的差异相互作用组将BIRC6鉴定为KRAS4A的泛素连接酶。
Cell Rep. 2025 Jan 28;44(1):115087. doi: 10.1016/j.celrep.2024.115087. Epub 2024 Dec 19.
7
Atypical Exon 2/3 Mutants G48C, Q43K, and E37K Present Oncogenic Phenotypes Distinct from Characterized NRAS Variants.非典型外显子 2/3 突变 G48C、Q43K 和 E37K 表现出与典型 NRAS 变异体不同的致癌表型。
Cells. 2024 Oct 12;13(20):1691. doi: 10.3390/cells13201691.
8
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.MYC 和 KRAS 合作:癌症治疗机遇中的历史挑战。
Signal Transduct Target Ther. 2024 Aug 21;9(1):205. doi: 10.1038/s41392-024-01907-z.
9
Cooperative genomic lesions in HRAS-mutant cancers predict resistance to farnesyltransferase inhibitors.HRAS 突变型癌症中的协同基因组病变预测对法尼酯转移酶抑制剂的耐药性。
Oncogene. 2024 Sep;43(37):2806-2819. doi: 10.1038/s41388-024-03095-0. Epub 2024 Aug 16.
10
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.KRAS 基因突变亚型及其与致癌通路中其他驱动基因突变的关联。
Cells. 2024 Jul 19;13(14):1221. doi: 10.3390/cells13141221.